Identification of potent inhibitors of HDAC2 from herbal products for the treatment of colon cancer: Molecular docking, molecular dynamics simulation, MM/GBSA calculations, DFT studies, and pharmacokinetic analysis
PLOS ONE · 22.07.2024 · 19 (7) · e0307501
DOI: 10.1371/journal.pone.0307501 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 22.07.2024. Verfasst von Madan Khanal und 7 weiteren Autor:innen. Beteiligte Einrichtung: Central Department of Physics, Tribhuvan University, Kathmandu, Nepal. Hauptthemen laut MEDLINE: Colonic Neoplasms, Molecular Dynamics Simulation, Molecular Docking Simulation, Histone Deacetylase 2. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The histone deacetylase 2 (HDAC2), an enzyme involved in gene regulation, is a potent drug target for the treatment of colon cancer. Phytocompounds having anticancer properties show the ability to interact with HDAC2 enzyme. Among the compounds, docking scores of caffeic acid (CA) and p -coumaric acid (pCA) with HDAC2 showed good binding efficacy of -5.46 kcal/mol and -5.16 kcal/mol, respectively, with small inhibition constants. The higher binding efficacy of CA compared to pCA can be credited to the presence of an extra oxygen atom in the CA molecule, which forms an additional hydrogen bond with Tyr297. The HDAC2 in complex with these molecules was found to be stable by analyzing RMSD, RMSF, R g , and SASA values obtained through MD simulations. Furthermore, CA and pCA exhibited low MM/GBSA free energies of -16.32 ± 2.62 kcal/mol and -17.01 ± 2.87 kcal/mol, respectively. The HOMO and LUMO energy gaps, dipole moments, global reactivity descriptor values, and MEP surfaces showed the reactivity of the molecules. The favourable physicochemical and pharmacokinetic properties, along with absence of toxicity of the molecules determined using ADMET analysis, suggested both the acids to be regarded as effective drugs in the treatment of colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Central Department of Physics, Tribhuvan University, Kathmandu, Nepal.
- Central Department of Chemistry, Tribhuvan University, Kathmandu, Nepal.
- Research Center for Applied Science and Technology (RECAST), Tribhuvan University, Kathmandu, Nepal.
- Nanomaterials Research Laboratory, Nepal Academy of Science and Technology (NAST), Lalitpur, Nepal.
ORCID-Profile: Madan Khanal
Zitieren
APA
Khanal, M., Acharya, A., Maharjan, R., Gyawali, K., Adhikari, R., Mulmi, D. D., Lamichhane, T. R., & Lamichhane, H. P. (2024). Identification of potent inhibitors of HDAC2 from herbal products for the treatment of colon cancer: Molecular docking, molecular dynamics simulation, MM/GBSA calculations, DFT studies, and pharmacokinetic analysis. PLOS ONE, 19(7), e0307501. https://doi.org/10.1371/journal.pone.0307501
Vancouver
Khanal M, Acharya A, Maharjan R, Gyawali K, Adhikari R, Mulmi DD, et al. Identification of potent inhibitors of HDAC2 from herbal products for the treatment of colon cancer: Molecular docking, molecular dynamics simulation, MM/GBSA calculations, DFT studies, and pharmacokinetic analysis. PLOS ONE. 2024;19(7):e0307501. doi:10.1371/journal.pone.0307501
BibTeX
@article{Khanal2024,
author = {Khanal, Madan and Acharya, Arjun and Maharjan, Rajesh and Gyawali, Kalpana and Adhikari, Rameshwar and Mulmi, Deependra Das and Lamichhane, Tika Ram and Lamichhane, Hari Prasad},
title = {Identification of potent inhibitors of HDAC2 from herbal products for the treatment of colon cancer: Molecular docking, molecular dynamics simulation, MM/GBSA calculations, DFT studies, and pharmacokinetic analysis},
journal = {PLOS ONE},
year = {2024},
volume = {19},
number = {7},
pages = {e0307501},
doi = {10.1371/journal.pone.0307501}
}
EUVIMED